Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Gene Therapy Market 

5.1. COVID-19 Landscape: Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Gene Therapy Market, By Vector

8.1. Gene Therapy Market, by Vector Type, 2023-2032

8.1.1. Viral Vector

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Non-viral Vector

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Gene Therapy Market, By Application

9.1. Gene Therapy Market, by Application, 2023-2032

9.1.1. Oncological Disorders

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Rare Diseases

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Cardiovascular Diseases

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Neurological Disorders

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Infectious Diseases

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Gene Therapy Market, By Gene 

10.1. Gene Therapy Market, by Gene, 2023-2032

10.1.1. Antigen

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Cytokine

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Tumor Suppressor

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Suicide

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Deficiency

10.1.5.1. Market Revenue and Forecast (2020-2032)

10.1.6. Receptors

10.1.6.1. Market Revenue and Forecast (2020-2032)

10.1.7. Others

10.1.7.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Gene Therapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Vector (2020-2032)

11.1.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.3. Market Revenue and Forecast, by Gene (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Vector (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Gene (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Vector (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Gene (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Vector (2020-2032)

11.2.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.3. Market Revenue and Forecast, by Gene (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Vector (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Gene (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Vector (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Gene (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Vector (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Gene (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Vector (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Gene (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Vector (2020-2032)

11.3.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.3. Market Revenue and Forecast, by Gene (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Vector (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Gene (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Vector (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Gene (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Vector (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Gene (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Vector (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Gene (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Vector (2020-2032)

11.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.3. Market Revenue and Forecast, by Gene (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Vector (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Gene (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Vector (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Gene (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Vector (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Gene (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Vector (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Gene (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Vector (2020-2032)

11.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.3. Market Revenue and Forecast, by Gene (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Vector (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Gene (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Vector (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Gene (2020-2032)

Chapter 12. Company Profiles

12.1. Dimension Therapeutics Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Taxus Cardium Pharmaceuticals Group Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Epeius Biotechnologies Corp.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Shanghai Sunway Biotech Co. Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Applied Genetic Technologies Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bristol-Myers Squibb Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. American Gene Technologies

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. BioMarin Pharmaceuticals Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Gensight Biologics S.A.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Sibinono GeneTech Co. Ltd

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms